PDF(Sci-hub)
Abstract：
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.
摘要：
T细胞淋巴细胞白血病（T-PLL）是一种罕见的，成熟的T细胞肿瘤具有异质性的临床过程。随着新的治疗方案的出现，可能会改变T-PLL患者的管理，有必要为临床试验的设计和实施制定共识指南。T-PLL国际研究小组（TPLL-ISG）着手定义诊断的标准化标准，治疗适应症,和反应评估。这些标准将有助于比较T-PLL临床试验的结果，因此将支持临床决策，以及医疗保健当局批准的新疗法。
